Show simple item record

dc.contributor.authorSingh, S
dc.contributor.authorCarnaghi, C
dc.contributor.authorBuzzoni, R
dc.contributor.authorPommier, R
dc.contributor.authorRaderer, M
dc.contributor.authorTomasek, J
dc.contributor.authorLahner, H
dc.contributor.authorValle, Juan W
dc.contributor.authorVoi, M
dc.contributor.authorBubuteishvili-Pacaud, L
dc.contributor.authorLincy, J
dc.contributor.authorWolin, E
dc.contributor.authorOkita, N
dc.contributor.authorLibutti, S
dc.contributor.authorOh, D
dc.contributor.authorKulke, M
dc.contributor.authorStrosberg, J
dc.contributor.authorYao, J
dc.contributor.authorPavel, M
dc.contributor.authorFazio, N
dc.date.accessioned2018-06-27T19:49:20Z
dc.date.available2018-06-27T19:49:20Z
dc.date.issued2018
dc.identifier.citationEverolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary. 2018, 106(3): 211-220 Neuroendocrinologyen
dc.identifier.issn1423-0194
dc.identifier.pmid28554173
dc.identifier.doi10.1159/000477585
dc.identifier.urihttp://hdl.handle.net/10541/621051
dc.description.abstractThe RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin.
dc.language.isoenen
dc.rightsArchived with thanks to Neuroendocrinologyen
dc.titleEverolimus in neuroendocrine tumors of the gastrointestinal tract and unknown primary.en
dc.typeArticleen
dc.contributor.departmentSunnybrook Health Sciences Centre, Toronto, ONen
dc.identifier.journalNeuroendocrinologyen
html.description.abstractThe RADIANT-4 randomized phase 3 study demonstrated significant prolongation of median progression-free survival (PFS) with everolimus compared to placebo (11.0 [95% CI 9.2-13.3] vs. 3.9 [95% CI 3.6-7.4] months) in patients with advanced, progressive, nonfunctional gastrointestinal (GI) and lung neuroendocrine tumors (NET). This analysis specifically evaluated NET patients with GI and unknown primary origin.


This item appears in the following Collection(s)

Show simple item record